Emer­gent to de­liv­er a $120M con­tract for the small­pox vac­cine for the US stock­pile

Emer­gent BioSo­lu­tions, a vac­cine and ther­a­peu­tic man­u­fac­tur­er for de­fense pur­pos­es, is ce­ment­ing its small­pox vac­cine pro­duc­tion sta­tus by ink­ing a con­tract with the US gov­ern­ment.

On Tues­day, Emer­gent an­nounced that it has a con­tract to de­liv­er the ACAM200 small­pox vac­cine to the Strate­gic Na­tion­al Stock­pile. Emer­gent said in a re­lease that this op­tion is the third of nine an­nu­al con­tract ex­ten­sions, with this ex­ten­sion be­ing worth around $120 mil­lion. The con­tract is al­so a part of Emer­gent’s 10-year, $2 bil­lion deal with HHS’s Of­fice of the As­sis­tant Sec­re­tary for Pre­pared­ness and Re­sponse set up in 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.